<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cardiovascular</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Wegovy pricing deal offers UK reimbursement for heart disease</title>
      <description>
        <![CDATA[Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed for the prevention of further serious cardiovascular events in people who have had a heart attack or stroke, or are diagnosed with peripheral arterial disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729982</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729982-wegovy-pricing-deal-offers-uk-reimbursement-for-heart-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Wegovy.webp?t=1691529296" type="image/jpeg" medium="image" fileSize="211081">
        <media:title type="plain">Wegovy </media:title>
        <media:description type="plain">Credit: Novo Nordisk A/S</media:description>
      </media:content>
    </item>
    <item>
      <title>Med-tech players join efforts to tackle UK PAD amputations</title>
      <description>
        <![CDATA[With cases of peripheral artery disease (PAD) rising across the U.K., and lower limb amputations continuing to increase, med-tech companies joined forces with parliamentarians and health care professionals to push for urgent reform of the vascular sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729981</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729981-med-tech-players-join-efforts-to-tackle-uk-pad-amputations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Peripheral-artery-disease-illustration.webp?t=1775074051" type="image/jpeg" medium="image" fileSize="424262">
        <media:title type="plain">Peripheral artery disease in leg artery</media:title>
      </media:content>
    </item>
    <item>
      <title>Braveheart finds phase II positive for cardiac myosin inhibitor </title>
      <description>
        <![CDATA[Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729968</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729968-braveheart-finds-phase-ii-positive-for-cardiac-myosin-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>TY-1 ameliorates hypertrophy in mice with HCM</title>
      <description>
        <![CDATA[Hypertrophic cardiomyopathy (HCM) is a condition that limits tolerance to exercise and predisposes people to sudden cardiac death due to mutations in sarcomeric genes. Researchers from Cedars-Sinai Medical Center have tested TY-1, a chemically modified oligonucleotide-based drug inspired by the previously tested EV-YF1, in mice with HCM.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730039</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730039-ty-1-ameliorates-hypertrophy-in-mice-with-hcm</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cardiology-genomics-genetics-illustration.webp?t=1751985662" type="image/jpeg" medium="image" fileSize="693008">
        <media:title type="plain">Illustration of heart analysis for DNA and drug impacts</media:title>
      </media:content>
    </item>
    <item>
      <title>Boston Sci boasts Champion-AF data but strokes signal a concern</title>
      <description>
        <![CDATA[Boston Scientific Corp. revealed much-anticipated data from the Champion-AF trial which showed that its Watchman FLX device provides superior protection from bleeding compared to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). The left atrial appendage closure device also proved noninferior to NOACs in reducing stroke, cardiovascular death, or systemic embolism.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729948</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729948-boston-sci-boasts-champion-af-data-but-strokes-signal-a-concern</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/09-26-Boston-Scientific-Watchman-FLX.webp?t=1774902951" type="image/png" medium="image" fileSize="547182">
        <media:title type="plain">Boston Scientific - Watchman FLX</media:title>
        <media:description type="plain">Watchman FLX. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Onkure Therapeutics to advance next-generation PI3Kα pan-mutant programs</title>
      <description>
        <![CDATA[Onkure Therapeutics Inc. has announced an oversubscribed $150 million private placement which the company intends to use to fund the preclinical and clinical development of its next-generation PI3Kα pan-mutant selective inhibitor candidates in breast cancer and vascular anomalies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729999</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729999-onkure-therapeutics-to-advance-next-generation-pi3k-pan-mutant-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Pink-and-orange-test-tubes.webp?t=1621456188" type="image/png" medium="image" fileSize="432197">
        <media:title type="plain">Pink and orange test tubes</media:title>
      </media:content>
    </item>
    <item>
      <title>Wave stock shaken, analysts stirred by 007’s obesity phase I </title>
      <description>
        <![CDATA[Apparently put off by data with a higher dose, investors in Wave Life Sciences Inc. backed away after the company rolled out data from the phase I portion of its first-in-human Inlight trial evaluating 250 mg of WVE-007, an INHBE GalNAc-siRNA prospect, in otherwise healthy overweight or obese adults.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729900</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729900-wave-stock-shaken-analysts-stirred-by-007s-obesity-phase-i</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/obesity-weight.webp?t=1589291306" type="image/png" medium="image" fileSize="227065">
        <media:title type="plain">Tape measure wrapped around feet on scale</media:title>
      </media:content>
    </item>
    <item>
      <title>SYW-06 improves cognitive function after MCAO</title>
      <description>
        <![CDATA[Sichuan Primed Shines Bio-Tech Co. Ltd. researchers have published results on their investigation regarding SYW-06 oral dosing and its impact on cognitive function in monkeys submitted to middle-cerebral artery occlusion (MCAO).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729933</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729933-syw-06-improves-cognitive-function-after-mcao</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/brain-stroke-ischemia.webp?t=1589298783" type="image/png" medium="image" fileSize="677072">
        <media:title type="plain">Stroke illustration: brain, artery, neurons</media:title>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729896</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729896-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Immutrin raises £65M series A to take another run at reversing amyloidosis</title>
      <description>
        <![CDATA[Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729825</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729825-immutrin-raises-65m-series-a-to-take-another-run-at-reversing-amyloidosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-scientific-overlay.webp?t=1729781889" type="image/jpeg" medium="image" fileSize="394419">
        <media:title type="plain">Heart scientific overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Immutrin to advance antibody for ATTR cardiomyopathy</title>
      <description>
        <![CDATA[Immutrin Ltd. has successfully raised £65 million ($87 million) in series A financing to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy. Immutrin’s novel antibody selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729856</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729856-financing-at-immutrin-to-advance-antibody-for-attr-cardiomyopathy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiology-heart-illustration.webp?t=1601070099" type="image/png" medium="image" fileSize="948393">
        <media:title type="plain">Colorful illustration of the heart</media:title>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729811</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729811-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Imperative secures $100M for thromboembolic technologies</title>
      <description>
        <![CDATA[Imperative Care Inc. secured $100 million through an oversubscribed convertible note financing round to support commercialization of its stroke and vascular thrombectomy technologies. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors alongside existing investor Catalio Capital Management LP. Also participating were new backers Longaeva Partners LP and Brown Advisory, with continued support from existing investors, including Ally Bridge Group and Bain Capital Life Sciences.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729561</guid>
      <pubDate>Wed, 18 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729561-imperative-secures-100m-for-thromboembolic-technologies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/thumb/symphony-18sept25.webp?t=1773858277" type="image/jpeg" medium="image" fileSize="53978">
        <media:title type="plain">Imperative Care Symphony</media:title>
        <media:description type="plain">Symphony Thrombectomy System. Credit: Imperative Care Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Structure’s oral GLP-1 data mark bullish year for obesity pills </title>
      <description>
        <![CDATA[The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729549</guid>
      <pubDate>Tue, 17 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729549-structures-oral-glp-1-data-mark-bullish-year-for-obesity-pills</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/GLP-1-capsule.webp?t=1766095755" type="image/jpeg" medium="image" fileSize="560029">
        <media:title type="plain">GLP-1 capsule</media:title>
      </media:content>
    </item>
    <item>
      <title>Samsung is adding trials and EHR access to Galaxy devices</title>
      <description>
        <![CDATA[Samsung Electronics Co. Ltd. is partnering with Verily Life Sciences LLC, an Alphabet Inc. company, and B.well Connected Health to turn Samsung Galaxy phones and smart watches into the “front door” of U.S. health care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729712</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729712-samsung-is-adding-trials-and-ehr-access-to-galaxy-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Samsung-bwell-EHR-3-11-26.webp?t=1773260633" type="image/jpeg" medium="image" fileSize="226460">
        <media:title type="plain">Screenshot of “Kill the Clipboard” app</media:title>
        <media:description type="plain">B.well and Samsung partner to bring “Kill the Clipboard” to life and reduce repetitive medical paperwork. Credit: B.well Connected Health</media:description>
      </media:content>
    </item>
    <item>
      <title>Samsung is adding trials and EHR access to Galaxy devices</title>
      <description>
        <![CDATA[Samsung Electronics Co. Ltd. is partnering with Verily Life Sciences LLC, an Alphabet Inc. company, and B.well Connected Health to turn Samsung Galaxy phones and smart watches into the “front door” of U.S. health care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729465</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729465-samsung-is-adding-trials-and-ehr-access-to-galaxy-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Samsung-bwell-EHR-3-11-26.webp?t=1773260633" type="image/jpeg" medium="image" fileSize="226460">
        <media:title type="plain">Screenshot of “Kill the Clipboard” app</media:title>
        <media:description type="plain">B.well and Samsung partner to bring “Kill the Clipboard” to life and reduce repetitive medical paperwork. Credit: B.well Connected Health</media:description>
      </media:content>
    </item>
    <item>
      <title>Taiwan to invest $752M in biopharma security over four years</title>
      <description>
        <![CDATA[Taiwan plans to invest NT$24 billion (US$752 million) over four years to bolster national biosecurity, expand domestic pharmaceutical production and safeguard against global supply chain volatility.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729579</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729579-taiwan-to-invest-752m-in-biopharma-security-over-four-years</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Taiwan-President-Lai-Ching-te-and-Healthy-Taiwan-Promotion-Committee-3-9.webp?t=1773090303" type="image/jpeg" medium="image" fileSize="506790">
        <media:title type="plain">Taiwan President Lai Ching-te presides over the seventh meeting of the Healthy Taiwan Promotion Committee.</media:title>
        <media:description type="plain">Taiwan President Lai Ching-te, center, presides over the seventh meeting of the Healthy Taiwan Promotion Committee.</media:description>
      </media:content>
    </item>
    <item>
      <title>Mixed phase II results still point to path forward for AISA-021</title>
      <description>
        <![CDATA[Although Aisa Pharma Inc’s cilnidipine (AISA-021) failed to meet the primary endpoint, multiple secondary endpoints showed statistically significant improvement in treating sclerosis-associated Raynaud's phenomenon, potentially positioning the drug for a phase III program in a disease with no approved oral therapies globally.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729578</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729578-mixed-phase-ii-results-still-point-to-path-forward-for-aisa-021</link>
    </item>
    <item>
      <title>Medtronic continues M&amp;A momentum with $550M Scientia Vascular buy</title>
      <description>
        <![CDATA[Medtronic plc has agreed to buy Scientia Vascular Inc. for $550 million, as it makes good on its promise to embark on more strategic acquisitions this year. The acquisition will bolster its neurovascular business as it adds a portfolio of guidewires and catheters, which uses Scientia’s microfabrication technology to simplify complex neurovascular procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729452</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729452-medtronic-continues-m-and-a-momentum-with-550m-scientia-vascular-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-MA-screen.webp?t=1710363128" type="image/jpeg" medium="image" fileSize="184805">
        <media:title type="plain">Hand pointing at digital M&amp;A screen</media:title>
      </media:content>
    </item>
    <item>
      <title>TN-301 restores muscle and cardiac function in DMD models</title>
      <description>
        <![CDATA[In Duchenne muscular dystrophy (DMD), deficiency of dystrophin leads to cardiomyocyte membrane instability, abnormal calcium influx, and progressive fibrotic remodeling of cardiac tissue. Histone deacetylase 6 (HDAC6) contributes to disease progression by regulating cytoskeletal dynamics and proteostasis in dystrophic muscle cells. Consequently, inhibition of HDAC6 represents a potential therapeutic strategy for addressing both the skeletal and cardiac manifestations of DMD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729510</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729510-tn-301-restores-muscle-and-cardiac-function-in-dmd-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Types-of-muscle-skeletal-cardiac-smooth.webp?t=1773155634" type="image/jpeg" medium="image" fileSize="380884">
        <media:title type="plain">Illustration showing the different types of muscle cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Taiwan to invest $752M in biopharma security over four years</title>
      <description>
        <![CDATA[Taiwan plans to invest NT$24 billion (US$752 million) over four years to bolster national biosecurity, expand domestic pharmaceutical production and safeguard against global supply chain volatility.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729440</guid>
      <pubDate>Mon, 09 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729440-taiwan-to-invest-752m-in-biopharma-security-over-four-years</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Taiwan-President-Lai-Ching-te-and-Healthy-Taiwan-Promotion-Committee-3-9.webp?t=1773090303" type="image/jpeg" medium="image" fileSize="506790">
        <media:title type="plain">Taiwan President Lai Ching-te presides over the seventh meeting of the Healthy Taiwan Promotion Committee.</media:title>
        <media:description type="plain">Taiwan President Lai Ching-te, center, presides over the seventh meeting of the Healthy Taiwan Promotion Committee.</media:description>
      </media:content>
    </item>
    <item>
      <title>Mixed phase II results still point to path forward for AISA-021</title>
      <description>
        <![CDATA[Although Aisa Pharma Inc’s cilnidipine (AISA-021) failed to meet the primary endpoint, multiple secondary endpoints showed statistically significant improvement in treating sclerosis-associated Raynaud's phenomenon, potentially positioning the drug for a phase III program in a disease with no approved oral therapies globally.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729439</guid>
      <pubDate>Mon, 09 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729439-mixed-phase-ii-results-still-point-to-path-forward-for-aisa-021</link>
    </item>
    <item>
      <title>Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets</title>
      <description>
        <![CDATA[Entering its first major cardiovascular disease collaboration with a biopharma company, while it advances two internal gene therapies, Tenaya Therapeutics Inc. signed on with Alnylam Pharmaceuticals Inc. to deliver up to 15 novel genetic targets that could lead to new heart disease medicines. The deal comes with $10 million up front, and up to $1.13 billion is available to South San Francisco-based Tenaya if all targets meet certain milestones, leading to approved therapeutics that Alnylam develops and commercializes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729477</guid>
      <pubDate>Fri, 06 Mar 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729477-tenaya-alnylam-join-in-1b-cardio-deal-for-novel-genetic-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-and-DNA.webp?t=1629916296" type="image/png" medium="image" fileSize="441817">
        <media:title type="plain">Heart and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Hengrui patents relaxin receptor 1 agonists</title>
      <description>
        <![CDATA[Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed amide-substituted cycloalkyl compounds acting as relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of heart failure and hypertension.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729402</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729402-hengrui-patents-relaxin-receptor-1-agonists</link>
    </item>
    <item>
      <title>Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets</title>
      <description>
        <![CDATA[Entering its first major cardiovascular disease collaboration with a biopharma company, while it advances two internal gene therapies, Tenaya Therapeutics Inc. signed on with Alnylam Pharmaceuticals Inc. to deliver up to 15 novel genetic targets that could lead to new heart disease medicines. The deal comes with $10 million up front, and up to $1.13 billion is available to South San Francisco-based Tenaya if all targets meet certain milestones, leading to approved therapeutics that Alnylam develops and commercializes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729341</guid>
      <pubDate>Thu, 05 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729341-tenaya-alnylam-join-in-1b-cardio-deal-for-novel-genetic-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-and-DNA.webp?t=1629916296" type="image/png" medium="image" fileSize="441817">
        <media:title type="plain">Heart and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Polares raises $50M for mitral valve system</title>
      <description>
        <![CDATA[Polares Medical SA raised $50 million in a series C financing round for Mrace, its posterior leaflet replacement system designed to treat mitral regurgitation. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729301</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729301-polares-raises-50m-for-mitral-valve-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-mitral-valve.webp?t=1611181711" type="image/png" medium="image" fileSize="397941">
        <media:title type="plain">3D rendering of heart, mitral valve</media:title>
      </media:content>
    </item>
    <item>
      <title>Returning to pulmonary hypertension, GSK buys 35Pharma </title>
      <description>
        <![CDATA[GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729368</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729368-returning-to-pulmonary-hypertension-gsk-buys-35pharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-heart-anatomy.webp?t=1772042014" type="image/jpeg" medium="image" fileSize="519932">
        <media:title type="plain">Lungs, heart anatomy </media:title>
      </media:content>
    </item>
    <item>
      <title>Jiuyuan seeks approval of Wegovy biosimilar in China</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729318</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729318-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china</link>
    </item>
    <item>
      <title>Theravance slashes R&amp;D as hypotension asset fails again</title>
      <description>
        <![CDATA[Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare disease multiple system atrophy, means the end of the company’s R&D efforts. Cutting its workforce in half and terminating all development of ampreloxetine, its only pipeline product, the Dublin-based company’s shares (NASDAQ:TBPH) sank by 26%, or $4.99, to close March 3 at $13.96.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729284</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729284-theravance-slashes-r-and-d-as-hypotension-asset-fails-again</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Layoff-shutdown-illustration.webp?t=1695155427" type="image/jpeg" medium="image" fileSize="146630">
        <media:title type="plain">Layoff, shutdown illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>NICE recommends leadless pacemakers to treat slow heart rhythms</title>
      <description>
        <![CDATA[The U.K.’s National Institute for Health and Care Excellence (NICE) recommendation that leadless cardiac pacemakers be used as the standard of care for people with slow heart rhythms (bradyarrhythmias) is a boon for more than 2 million individuals living with the condition. The use of the technology will transform patients’ quality of life, reduce rates of infections and lower costs for the health care system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729270</guid>
      <pubDate>Mon, 02 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729270-nice-recommends-leadless-pacemakers-to-treat-slow-heart-rhythms</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Abbott-Laboratories-Aveir-VR-leadless-pacemaker-system-3-2.webp?t=1772486511" type="image/jpeg" medium="image" fileSize="82525">
        <media:title type="plain">Abbott Laboratories Aveir VR leadless pacemaker system</media:title>
        <media:description type="plain">Aveir VR leadless pacemaker system. Credit: Abbott Laboratories 
</media:description>
      </media:content>
    </item>
  </channel>
</rss>
